期刊文献+

优泌乐25、来得时和诺和锐30治疗2型糖尿病临床疗效分析 被引量:2

下载PDF
导出
摘要 目的:观察优泌乐25、来得时和诺和锐30治疗2型糖尿病的临床疗效。方法:将97例经口服药治疗无效的2型糖尿病患者,随机分为3组,分别给予优泌乐25(34例)、来得时(30例)和诺和锐30(33例),优泌乐25及诺和锐30早、晚餐前注射,来得时睡前注射1次联合口服拜唐苹,均治疗12周,观察3组患者空腹血糖(fasting plasma glucose,FPG)、餐后2 h血糖(2-hour postprandial blood glucose,2hPG)、糖化血红蛋白(hemoglobin A1c,HbA1c)、血清糖化白蛋白(glycated albumin,GA)、胰岛素用量、血糖达标时间、体质量指数(body mass index,BMI)、低血糖的发生情况等各项指标的变化,并比较治疗效果。结果:3组患者治疗后FPG、2hPG、HbA1c、GA水平均明显低于治疗前(P<0.05);来得时组较其他2组治疗后HbA1c水平更低,胰岛素用量少,低血糖发生率低,差异有统计学意义(P<0.05)。结论:来得时联合拜唐苹治疗2型糖尿病,能在保持患者血糖平稳的同时降低低血糖的发生率,且能减少胰岛素用量,是目前治疗2型糖尿病的较佳方案,值得临床推广应用。
作者 赵芬 许燕
出处 《南通大学学报(医学版)》 2013年第6期556-557,共2页 Journal of Nantong University(Medical sciences)
  • 相关文献

参考文献5

二级参考文献9

  • 1潘长玉,田慧,刘国良,李秀钧,傅祖植,陈家伟,暨亚洲糖尿病管理中国协作组.中国城市中心医院糖尿病健康管理调查[J].中华内分泌代谢杂志,2004,20(5):420-424. 被引量:193
  • 2Wei M, Mitchell BD, Haffner SM, et al. Effects of cigarette smoking, diabetes, high cholesterol and lypertension on all cause mortality and cardiovascular disease mortality in Mexican Americans. Am J Epidemiol, 1996,144 : 1058-1065.
  • 3Wada T, Furuichi K, Sakai N, et al. Regulation of monocyte chemoattractant protein in tubulointerstitial lesions of human diabetic nephropathy. Kidney Int,2000,58 : 1492-1499.
  • 4Dandona P, Aljada A, Mohanty P, et al. Insulin inhibits intranuclear nuclear factor kappaB and stimulates IkappaB in mononuclear ceils in obese subjects :evidence for an anti-inflammatory effect? J Clin Endocrinol Metab ,2001,86:3257-3265.
  • 5Lazarou J, Pomeranz BH, Corey PN, et al. Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies. JAMA, 1998, 279:1200-1205.
  • 6IDF Clinical Guidelines Task Force. Global Guidelines for Type 2 Diabetes: recommendations for standard, comprehensive, and minimal care. Diabet Med, 2006,23:579-593.
  • 7Buse JB, GinsbergHN, Bakris GL, et al. Primary prevention of cardiovascular diseases in people with diabetes mellitus: a scientific statement from the American Heart Association and the American Diabetes Association.Diabetes Care, 2007,30 : 162-172.
  • 8Nissen SE, Wolski K, Topoi EJ. Effect of muraglitazar on death and major adverse cardiovascular events in patients with type 2 diabetes mellitus. JAMA, 2005,294:2581-2586.
  • 9Janka HU, Plewe G, Riddle MC, et al. Comparison of basal insulin added to oral agents versus twice-daily premixed insulin as initial insulin therapy for type 2 diabetes. Diabetes Care, 2005, 28:254-259.

共引文献59

同被引文献96

引证文献2

二级引证文献9

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部